Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy of prophylaxis with oral vancomycin for preventing
recurrent Clostridium difficile Infection (CDI) in patients who have experienced at least one
CDI episode in the last 180 days and are receiving antibiotics for a non CDI condition.
Participants will be randomized to receive either placebo or oral vancomycin in addition to
their prescribed antibiotic therapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborators:
Agency for Healthcare Research and Quality (AHRQ) Henry Ford Hospital Indiana University Medical College of Wisconsin